SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.

The purpose of this study is to evaluate level of test medication with respect to time in the body, and safety when compared with the reference medication Subject will be randomly assigned to receive an intravenous infusion of either SPARC1613 delivered over 25 (±1) minutes or Reference1613 delivered over 30 (±1) minutes

Inclusion Criteria:

• The subject has given written, informed consent and is available for the duration of study
• Histologically or cytologically confirmed diagnosis of breast cancer
• Male or female aged ≥ 18 years
• Females subjects of child-bearing potential must have a negative urine pregnancy test
• Female subjects must be non-lactating and non-breastfeeding
• Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing

Exclusion Criteria:

• Known hypersensitivity to either of the study drugs or their excipients
• Inability to undergo venipuncture and/or tolerate venous access
• Pre-existing clinically significant peripheral neuropathy
• Positive laboratory exclusion test (HIV, HBsAg, or HCV)
• Treatment with investigational agents or participation in clinical trial within 30 days of study entry